Skip to main
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is poised for success with a strong financial backing of $50M tranche and two $25M tranches through the K2 financing. Positive results from the upcoming AURORA and HELIOS trials in 1H:2027 have the potential to open up an avenue for rare pediatric disease designation (RPDD) and a Priority Review Voucher (PRV) for Descartes-08, supporting its potential for success in treating patients with autoimmune diseases. The multiple potential paths for approval, coupled with positive interim data from the TRITON study, make Cartesian Therapeutics a promising investment opportunity.

Bears say

Cartesian Therapeutics is facing significant risks in their clinical trials, with uncertainties surrounding the efficacy and safety of their lead programs, Descartes-08 and Vyvgart, which are being evaluated for multiple autoimmune conditions. In addition, potential delays in regulatory approvals and challenges in manufacturing and distribution may impact the company's ability to attain sales estimates. Given these uncertainties, as well as the focus on their near-term program AURORA, we have a negative outlook on RNAC's stock.

RNAC has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 5 analysts, RNAC has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.